Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2609.50
CVM's Cash to Debt is ranked higher than
55% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CVM: 2609.50 )
Ranked among companies with meaningful Cash to Debt only.
CVM' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 836.79 Max: No Debt
Current: 2609.5
Equity to Asset -0.26
CVM's Equity to Asset is ranked lower than
95% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CVM: -0.26 )
Ranked among companies with meaningful Equity to Asset only.
CVM' s Equity to Asset Range Over the Past 10 Years
Min: -0.51  Med: 0.67 Max: 0.99
Current: -0.26
-0.51
0.99
F-Score: 2
Z-Score: -30.49
M-Score: 24.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -22694.92
CVM's Operating margin (%) is ranked lower than
96% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. CVM: -22694.92 )
Ranked among companies with meaningful Operating margin (%) only.
CVM' s Operating margin (%) Range Over the Past 10 Years
Min: -190240  Med: -11287.71 Max: -1881.38
Current: -22694.92
-190240
-1881.38
Net-margin (%) -17115.25
CVM's Net-margin (%) is ranked lower than
95% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CVM: -17115.25 )
Ranked among companies with meaningful Net-margin (%) only.
CVM' s Net-margin (%) Range Over the Past 10 Years
Min: -154060  Med: -6210.31 Max: 6851.63
Current: -17115.25
-154060
6851.63
ROA (%) -116.16
CVM's ROA (%) is ranked lower than
88% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. CVM: -116.16 )
Ranked among companies with meaningful ROA (%) only.
CVM' s ROA (%) Range Over the Past 10 Years
Min: -199.98  Med: -90.18 Max: 25.01
Current: -116.16
-199.98
25.01
ROC (Joel Greenblatt) (%) -9249.83
CVM's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. CVM: -9249.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CVM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9249.83  Med: -1101.41 Max: 687.95
Current: -9249.83
-9249.83
687.95
Revenue Growth (3Y)(%) -7.20
CVM's Revenue Growth (3Y)(%) is ranked lower than
64% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CVM: -7.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CVM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.3 Max: 18.6
Current: -7.2
0
18.6
EBITDA Growth (3Y)(%) -10.60
CVM's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CVM: -10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CVM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.5  Med: -12.5 Max: 17.1
Current: -10.6
-51.5
17.1
EPS Growth (3Y)(%) -18.60
CVM's EPS Growth (3Y)(%) is ranked lower than
66% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CVM: -18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CVM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -51  Med: -16.7 Max: 41.3
Current: -18.6
-51
41.3
» CVM's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-02-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PMCB, NAS:APVO, OTCPK:PTIX, AMEX:RNN, OTCPK:EMIS, NAS:DNAI, NAS:TPIV, NAS:AEZS, NAS:XOMA, NAS:EARS, NAS:DMPI, AMEX:IBIO, OTCPK:ORGS, OTCPK:PTGEF, NAS:GALE, OTCPK:BIOAF, AMEX:OGEN, NAS:DFFN, NAS:THLD, NAS:VSTM » details
Traded in other countries:LSRN.Germany,
CEL-SCI Corp is a biotechnology company. It is engaged in the research & development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products. The Company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. Its investigational therapy, Multikine, is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase 1 and Phase 2 clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with CEL-SCI's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use. Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines and is manufactured in a proprietary manner in its manufacturing facility. The Company's patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. Administered like a vaccine, LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.

Ratios

vs
industry
vs
history
Current Ratio 1.62
CVM's Current Ratio is ranked lower than
79% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CVM: 1.62 )
Ranked among companies with meaningful Current Ratio only.
CVM' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 6.17 Max: 160
Current: 1.62
0.17
160
Quick Ratio 1.39
CVM's Quick Ratio is ranked lower than
78% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CVM: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
CVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 5.93 Max: 160
Current: 1.39
0.04
160
Days Sales Outstanding 2.00
CVM's Days Sales Outstanding is ranked higher than
95% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CVM: 2.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2  Med: 168.81 Max: 230.53
Current: 2
2
230.53

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -60.20
CVM's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CVM: -60.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.2  Med: -25.9 Max: -10.6
Current: -60.2
-60.2
-10.6

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -250.79
CVM's Earnings Yield (Greenblatt) (%) is ranked lower than
99% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. CVM: -250.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CVM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -250.79  Med: 5.45 Max: 13.9
Current: -250.79
-250.79
13.9

More Statistics

Revenue (TTM) (Mil) $0.12
EPS (TTM) $ -0.18
Beta-1.26
Short Percentage of Float2.22%
52-Week Range $0.11 - 0.66
Shares Outstanding (Mil)145.35

Analyst Estimate

Sep16 Sep17 Sep18
Revenue (Mil $) 1 2 2
EPS ($) -0.41 -0.34 0.34
EPS w/o NRI ($) -0.41 -0.34 0.34
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CVM

Headlines

Articles On GuruFocus.com
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 
CELSCISci Corp Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
7:02 am CEL-SCI Corp prices a $4.25 mln public offering of about 34.02 mln shares of common stock... Dec 02 2016
CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants Dec 02 2016
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants Dec 01 2016
NEW STORY CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3... Nov 21 2016
CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial Nov 21 2016
NEW STORY CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine Is Successful In Treating... Nov 14 2016
CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid... Nov 14 2016
NEW STORY CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial Oct 21 2016
CEL-SCI Provides Update on Partial Clinical Hold on Phase 3 Clinical Trial Oct 21 2016
ETF’s with exposure to CEL-SCI Corp. : October 18, 2016 Oct 18 2016
CVR Medical Retains Brisco Capital Investor Relations Sep 30 2016
CEL SCI CORP Files SEC form 8-K, Other Events Sep 28 2016
Bank of America Corp (BAC), Carnival Corp (CCL) & More: 5 Stocks Making Morning Moves Sep 27 2016
NEW STORY CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study Sep 26 2016
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study Sep 26 2016
IIROC Trading Resumption - CVM Sep 26 2016
IIROC Trading Resumption - CVM Sep 26 2016
ETF’s with exposure to CEL-SCI Corp. : September 14, 2016 Sep 14 2016
NEW STORY CEL-SCI Announces Resignation of Its Founder for Health Reasons Sep 06 2016
CEL-SCI Announces Resignation of its Founder for Health Reasons Sep 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)